Akebia Therapeutics, Inc.

NASDAQ:AKBA

Biotechnology

Healthcare
$0.41 +0.49%

+$0.01 today

Market cap
$113.54M
Beta
0.25
P/E (TTM)
-13.3
EPS (TTM)
-$0.08
52W Low $0.82High $4.08

Volume 7.09M

Average 4.03M

AKBA Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Akebia Therapeutics, Inc.NASDAQ: AKBA

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation grows in line with its trailing trend

Q1 FY2026 stock-based compensation of $3.67M rose 67.7% year over year, in line with the +67.9% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 14.7% from the prior quarter. Over 3 fiscal years it compounded at -14.2% a year.

Context

  • Stock-based compensation amounted to 4.8% of revenue in FY2025, unchanged from a year earlier.
  • Stock-based compensation increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +67.7% toward the trailing-twelve-month pace of +67.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.67M+14.7% QoQ
Last fiscal yearDec 2025
$11.28M+45.1% YoY
LTMMar 2026
$12.76M+67.9% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+67.7%——
1 year+45.1%——
3-year CAGR-14.2%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
11.28M USD
Year-over-year change
+45.1%
4-year CAGR
-16.1%

Stock-Based Compensation vs competitors

How AKBA compares with its peers on the latest reported figures

  • AKBA's LTM Mar 2026 stock-based compensation of $12.76M is the 6th largest of the 10 companies compared; the peer median is $12.84M.
  • Its year-over-year change of +67.9% is the 2nd highest of 9, against a peer median of -18.3%.
  • Stock-based compensation amounts to 5.5% of revenue for AKBA, versus a peer median of 16.2%.
AKBA Competitors Peer median
Stock-Based Compensation for AKBA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
PRTAProthena Corporation plcLTM Mar 2026$33.61M -24.5%+6.3%58.0%
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026$19.48M -28.2%+8.7%22.1%
GOSSGossamer Bio, Inc.LTM Mar 2026$14.45M -16.0%-37.2%26.0%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026$13.21M -40.1%——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$12.84M +21.4%+0.9%4.3%
AKBAAkebia Therapeutics, Inc.LTM Mar 2026$12.76M +67.9%-14.2%5.5%
ZVRAZevra Therapeutics, Inc.LTM Mar 2026$12.62M -20.6%+43.3%10.3%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$10.93M +20.5%+16.2%—
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$6.73M +88.8%+25.6%—
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$5.38M ——4.6%
Peer median (excluding AKBA) $12.84M-18.3%+8.7%16.2%

Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(282.02M)(92.56M)(51.93M)(69.41M)(5.35M)
Depreciation & Amortization36.13M37.7M41.85M37.5M1.27M
Deferred Income Tax00000
Stock-Based Compensation22.74M17.85M9.32M7.78M11.28M
Change in Working Capital(105.61M)(1.44M)(20.73M)(39.68M)16.47M
Accounts Receivables(24.03M)11.7M994K4.05M(14.14M)
Inventory(24.95M)19.79M(2.54M)(28.4M)(23.13M)
Accounts Payables(11.74M)1.5M(5.24M)(1.36M)3.08M
Other Working Capital(44.9M)(34.42M)(13.94M)(13.96M)50.66M
Other Non-Cash Items98.54M(34.7M)(1.9M)23.15M44.31M
Operating Cash Flow(252.97M)(73.15M)(23.38M)(40.66M)67.99M
Capital Expenditures(59K)(114K)0(33K)(291K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments40M0000
Other Investing Activities0000(7.93M)
Investing Cash Flow39.94M(114K)0(33K)(7.93M)
Debt Repayment44.78M(33M)(32M)7.9M4.63M
Common Stock Issued88.95M7.53M6.79M42.65M68.36M
Common Stock Repurchased000(1.27M)0
Dividends Paid00000
Other Financing Activities040.07M1K385K(63K)
Financing Cash Flow133.73M14.6M(25.21M)49.66M72.93M
Effect of Forex Changes00000
Net Change in Cash(79.29M)(58.67M)(48.59M)8.97M132.99M
Free Cash Flow(253.02M)(73.27M)(23.38M)(40.69M)67.99M

Akebia Therapeutics, Inc.

NASDAQ:AKBA

Intrinsic Alpha fair value

Locked

Current Price

$0.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.